Last reviewed · How we verify
JNJ-38877618: Part 2
At a glance
| Generic name | JNJ-38877618: Part 2 |
|---|---|
| Sponsor | Janssen Cilag N.V./S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- OMO-1 in Solid Malignancies (PHASE1, PHASE2)
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-38877618: Part 2 CI brief — competitive landscape report
- JNJ-38877618: Part 2 updates RSS · CI watch RSS
- Janssen Cilag N.V./S.A. portfolio CI